Drug intelligence / Profile preview

L30

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical

Overview

L30 is a novel small molecule phosphodiesterase 4 (PDE4) inhibitor. It was developed through structure-based optimization of the natural product moracin M, demonstrating significantly improved potency with an IC50 of 8.6 nM and remarkable selectivity (over 201-fold) against other PDE families. L30 effectively inhibits the release of inflammatory cytokines and chemokines in Raw264.7 and HaCaT cell lines. It has shown significant therapeutic effects in an imiquimod-induced psoriasis mouse model, indicating its potential as a treatment for psoriasis.

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on L30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L30.

Explore the full profile